- Shuen-Kuei Liao, PhD
- The PhD Program for Cancer Biology and Drug Discovery, Taipei Medical University, Taipei 110, Taiwan, China.
Website | E-mail
Special Issue Introduction
This special issue covering seven articles in the area of cancer Immunotherapy/biotherapy provides useful source information as well as a landmark at an extremely exciting time in the development of many innovative immune/biological agents, such as non-specific immunomodulators, immune checkpoint molecules, humanized antibodies, genetically modified T cells and neoantigen/RNA mutanome vaccines. The invited authors have covered the scientific principles, technologies, experimental models, clinical approaches and future directions in their own ways. We do not intend to remove areas of overlapping among articles particularly the review articles, so that a variety of perspectives could be presented on the different approaches to the many laboratory and clinical problems. Just as important, strategies with individualized and combinational (with any standard treatment) approaches for greater efficacies have been much emphasized in this type of treatment modality. While currently only small proportions of patients with selected cancer types refractory to the standard therapies have benefitted, some major scientific, clinical and regulatory hurdles still need to be overcome in order to bring the full potential clinical benefits in years to come. I sincerely hope that this special issue will give our readers a snapshot of this exciting and evolving new field.
KeywordsCancer immunology and immunotherapy, hyperthermia, uveal melanoma, hepatocellular catcinoma, liver microenvironment, immune checkpoint inhibitors, chimeric antibodies, NK cells, dendritic cells, cytotoxic T-lymphocytes, CAR-T cells, neoantigen/RNA mutanome vaccines, metastasis, cancer stem cells, combinational therapy
Submission Deadline 2 Oct 2017